Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

Pfizer names oncology head Chris Boshoff as R&D chief

admin by admin
November 20, 2024
in Stock
0
Pfizer names oncology head Chris Boshoff as R&D chief
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

(Reuters) – Pfizer (NYSE:PFE) said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and development.

The appointment comes at a time when Pfizer is facing criticism from activist investor Starboard for overspending on big acquisitions and failing to produce profitable new drugs from those deals or its internal research and development.

The New York-based drugmaker, under CEO Albert Bourla, poured money into new deals to bolster its business, which has been struggling with a sharp fall in sales of its COVID vaccine and antiviral Paxlovid from the pandemic highs.

Pfizer, which is now looking to strengthen its focus on cancer drugs, said Boshoff will take on the role of chief scientific officer starting Jan. 1 and oversee all functions of research & development across all therapeutic areas.

Most recently Pfizer’s chief oncology officer, Boshoff, also served as chief development officer for oncology and rare diseases, and as head of development in Japan across all therapeutic areas at Pfizer.

He has been with Pfizer for more than 11 years and has overseen the approval of 24 innovative medicines and biosimilars in more than 30 conditions.

Boshoff will replace Mikael Dolsten, a key figure behind the development of Pfizer’s COVID-19 vaccine, who stepped down from the role earlier this year after a more than 15-year career at the drugmaker.

Roger Dansey, who joined Pfizer through the 2023 $43-billion Seagen acquisition, will serve as the interim chief oncology officer, the company said.

The drugmaker added Johanna Bendell, who will join the company from Roche in 2025, will take on the role as oncology chief development officer.

This post appeared first on investing.com

Previous Post

Delta Air eyes mid single-digit revenue growth in 2025 with premium travel in focus

Next Post

Delta Air Lines is in the ‘best fundamental shape it has ever been in’

admin

admin

Next Post
Delta Air Lines is in the ‘best fundamental shape it has ever been in’

Delta Air Lines is in the ‘best fundamental shape it has ever been in’

Trending News

What is the potential impact of the US election on Mexico

What is the potential impact of the US election on Mexico

October 20, 2024
Assassin’s Creed maker’s shares plunge 18% after Q1 results: here’s why

Assassin’s Creed maker’s shares plunge 18% after Q1 results: here’s why

May 15, 2025
US tariffs fuel inflation, putting pressure on low-income households

US tariffs fuel inflation, putting pressure on low-income households

March 11, 2025
Subscribe to Insightful Word


    Recent News

    ARB eyes recovery as Arbitrum taps agentic DeFi revolution with $1M grant

    ARB eyes recovery as Arbitrum taps agentic DeFi revolution with $1M grant

    June 5, 2025
    Ripple releases $2.18B in XRP, price dips 2%

    Ripple releases $2.18B in XRP, price dips 2%

    June 5, 2025
    Nintendo Switch 2 launch sees shortages as 2.2M vie for units in Japan

    Nintendo Switch 2 launch sees shortages as 2.2M vie for units in Japan

    June 5, 2025
    Why Bank of America sees 13% upside on Roblox (RBLX)

    Why Bank of America sees 13% upside on Roblox (RBLX)

    June 5, 2025

    Recent News

    ARB eyes recovery as Arbitrum taps agentic DeFi revolution with $1M grant

    ARB eyes recovery as Arbitrum taps agentic DeFi revolution with $1M grant

    June 5, 2025
    Ripple releases $2.18B in XRP, price dips 2%

    Ripple releases $2.18B in XRP, price dips 2%

    June 5, 2025

    Latest News

    • ARB eyes recovery as Arbitrum taps agentic DeFi revolution with $1M grant
    • Ripple releases $2.18B in XRP, price dips 2%
    • Nintendo Switch 2 launch sees shortages as 2.2M vie for units in Japan

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.